Richard Soucier, MD
Cardiovascular Disease · Hartford, CTNPI 1255334207
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $79,550 of the $96,665 with a category attached, or 82.3%. Novartis accounts for 64.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $92,083 and has fallen 99.4% since, to $572 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $604.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$62K
- Johnson & Johnson$17K
- Boehringer Ingelheim$8K
- Abbott$5K
- Bayer$2K
- Medtronic$1K
- plus $2K from 14 others
Across 16 payments — averaging $2381.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$23K
- Sanofi US Services Inc.$16K
What the payments were for
- Consulting fees$6,6107%
- Speaking & faculty fees$79,55082%
- Travel & lodging$6,2636%
- Food & beverage$4,2224%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 65 | $62,167 |
| Johnson & Johnson | 18 | $16,866 |
| Boehringer Ingelheim | 12 | $7,763 |
| Abbott | 10 | $5,194 |
| Bayer | 2 | $1,780 |
| Medtronic | 1 | $1,060 |
| Lilly USA, LLC | 3 | $782 |
| E.r. Squibb & Sons, L.L.C. | 12 | $289 |
| Pfizer | 14 | $269 |
| Amgen | 3 | $75 |
| AstraZeneca | 3 | $69 |
| Corcept Therapeutics | 3 | $64 |
| Lexicon Pharmaceuticals, Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Actelion Pharmaceuticals US, Inc. | 2 | $52 |
| Scpharmaceuticals Inc. | 2 | $41 |
| GSK | 1 | $29 |
| Baxter Healthcare | 1 | $26 |
| Novo Nordisk | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$61,235
- XARELTO$16,402
- JARDIANCE$8,278
- CardioMEMS HF System$4,915
- Kerendia$1,760
- Confirm Rx$124
How this compares
$96,665 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 77 | $87,244 |
| EliquisApixaban | 83 | $70,869 |
| JardianceEmpagliflozin | 60 | $62,368 |
| FarxigaDapagliflozin Propanediol | 67 | $57,421 |
| XareltoRivaroxaban | 59 | $55,292 |
| Spironolactone | 172 | $1,452 |
| Metoprolol Succinate | 92 | $1,043 |
| Furosemide | 183 | $1,011 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 26 | $751 |
| Valsartan | 30 | $615 |
| Torsemide | 20 | $493 |
| Bumetanide | 14 | $479 |
| Amiodarone Hcl | 13 | $458 |
| Ezetimibe | 19 | $343 |
| Carvedilol | 55 | $297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $62,167 | $87,24477 claims |
| PfizerEliquis | $269 | $70,86983 claims |
| Boehringer IngelheimJardiance | $7,763 | $62,36860 claims |
| AstraZenecaFarxiga | $69 | $57,42167 claims |
| Johnson & JohnsonXarelto | $16,866 | $55,29259 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Hartford
- Stephanie SaucierHartford$243K
- Antonio FernandezHartford$113K
- Paul ThompsonHartford$108K
- Atique MirzaHartford$29K
- Sean McMahonHartford$23K
- Lonny ReismanHartford$22K
- David HenryHartford$13K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.